mk-7655 and Escherichia-coli-Infections

mk-7655 has been researched along with Escherichia-coli-Infections* in 1 studies

Other Studies

1 other study(ies) available for mk-7655 and Escherichia-coli-Infections

Article	Year
Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Antimicrobial agents and chemotherapy, 2020, 04-21, Volume: 64, Issue:5 Imipenem-relebactam (I-R) is a recently developed carbapenem-beta-lactamase inhibitor combination agent that can overcome carbapenem resistance, which has now emerged in Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Genotype; Geography; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; United States	2020

Article

Year

Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.

Antimicrobial agents and chemotherapy, 2020, 04-21, Volume: 64, Issue:5

Imipenem-relebactam (I-R) is a recently developed carbapenem-beta-lactamase inhibitor combination agent that can overcome carbapenem resistance, which has now emerged in

Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Genotype; Geography; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; United States

2020